看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 23.7x - 26.2x | 25.0x |
| Selected Fwd P/E Multiple | 13.3x - 14.7x | 14.0x |
| Fair Value | €194.90 - €215.42 | €205.16 |
| Upside | -17.4% - -8.7% | -13.1% |
| Benchmarks | - | Full Ticker |
| Quest Diagnostics Incorporated | - | NYSE:DGX |
| Cryo-Cell International, Inc. | - | NYSEAM:CCEL |
| Guardant Health, Inc. | - | NasdaqGS:GH |
| OPKO Health, Inc. | - | NasdaqGS:OPK |
| Precipio, Inc. | - | NasdaqCM:PRPO |
| Labcorp Holdings Inc. | - | DB:N6B |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| DGX | CCEL | GH | OPK | PRPO | N6B | |||
| NYSE:DGX | NYSEAM:CCEL | NasdaqGS:GH | NasdaqGS:OPK | NasdaqCM:PRPO | DB:N6B | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 0.7% | -29.4% | NM- | NM- | NM- | -2.0% | ||
| 3Y CAGR | -24.2% | -42.2% | NM- | NM- | NM- | -30.2% | ||
| Latest Twelve Months | 13.0% | 98.2% | 15.7% | 27.1% | 53.0% | 69.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 12.9% | 0.0% | -95.1% | -15.1% | -90.5% | 9.6% | ||
| Prior Fiscal Year | 9.2% | -30.4% | -85.0% | -21.9% | -38.5% | 3.1% | ||
| Latest Fiscal Year | 8.8% | 1.3% | -59.0% | -7.5% | -23.1% | 5.7% | ||
| Latest Twelve Months | 9.0% | -0.5% | -49.9% | -26.7% | -8.5% | 5.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 13.0x | 10.0x | -20.2x | -7.0x | -20.1x | 15.9x | ||
| Price / LTM Sales | 2.0x | 1.1x | 9.2x | 1.6x | 1.1x | 1.7x | ||
| LTM P/E Ratio | 21.7x | -214.0x | -18.5x | -6.2x | -13.0x | 30.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -214.0x | -13.0x | 21.7x | |||||
| Historical LTM P/E Ratio | 10.9x | 23.5x | 44.0x | |||||
| Selected P/E Multiple | 23.7x | 25.0x | 26.2x | |||||
| (x) LTM Net Income | 763 | 763 | 763 | |||||
| (=) Equity Value | 18,128 | 19,082 | 20,036 | |||||
| (/) Shares Outstanding | 83.1 | 83.1 | 83.1 | |||||
| Implied Value Range | 218.15 | 229.63 | 241.11 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 188.13 | 198.03 | 207.93 | 236.00 | ||||
| Upside / (Downside) | -20.3% | -16.1% | -11.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DGX | CCEL | GH | OPK | PRPO | N6B | |
| Value of Common Equity | 20,544 | 37 | 7,642 | 1,095 | 23 | 22,741 | |
| (/) Shares Outstanding | 111.8 | 8.1 | 124.7 | 793.8 | 1.6 | 83.1 | |
| Implied Stock Price | 183.72 | 4.55 | 61.28 | 1.38 | 14.50 | 273.65 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 183.72 | 4.55 | 61.28 | 1.38 | 14.50 | 236.00 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |